Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Receivables: 2021-2024

Historic Change in Receivables for Apellis Pharmaceuticals (APLS) over the last 4 years, with Dec 2024 value amounting to $58.5 million.

  • Apellis Pharmaceuticals' Change in Receivables rose 616.91% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year decrease of 39.39%. This contributed to the annual value of $58.5 million for FY2024, which is 70.57% down from last year.
  • Apellis Pharmaceuticals' Change in Receivables amounted to $58.5 million in FY2024, which was down 70.57% from $198.7 million recorded in FY2023.
  • Apellis Pharmaceuticals' 5-year Change in Receivables high stood at $198.7 million for FY2023, and its period low was -$2.4 million during FY2022.
  • Moreover, its 3-year median value for Change in Receivables was $58.5 million (2024), whereas its average is $84.9 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 123.51% in 2022, then surged by 8,466.95% in 2023.
  • Apellis Pharmaceuticals' Change in Receivables (Yearly) stood at $10.1 million in 2021, then crashed by 123.51% to -$2.4 million in 2022, then skyrocketed by 8,466.95% to $198.7 million in 2023, then tumbled by 70.57% to $58.5 million in 2024.